Table 5.
Predictors of Type of Bladder Antimuscarinics Initiation Using Imputed Values in All New Users (n = 12,899)
| New non-selective ER user vs. New non-selective IR user | New selective user vs. new non-selective IR user | |
|---|---|---|
| OR (95% CI) | OR (95% CI) | |
| Age Group | ||
| 65 to 74 | Ref. | Ref. |
| 75 to 84 | 1.019 (0.900–1.153) | 0.956 (0.808–1.130) |
| 85 and Older | 0.863 (0.760–0.980)a | 0.884 (0.745–1.050) |
| Female | 1.279 (1.145–1.428)a | 1.324 (1.139–1.539)a |
| Race | ||
| White | Ref. | Ref. |
| Black | 1.269 (1.078–1.494)a | 0.925 (0.734–1.165) |
| Other Race | 1.019 (0.789–1.316) | 1.269 (0.898–1.793) |
| Nursing Home Region | ||
| Midwest | Ref. | Ref. |
| Northeast | 0.627 (0.561–0.700)a | 0.575 (0.489–0.675)a |
| South | 0.651 (0.587–0.723) | 1.043 (0.911–1.193) |
| West | 0.868 (0.727–1.036) | 0.630 (0.483–0.821)a |
| Body Mass Index | ||
| Underweight | 0.785 (0.670–0.919)a | 0.684 (0.539–0.869)a |
| Normal | Ref. | Ref. |
| Overweight | 1.085 (0.978–1.204) | 1.198 (1.042–1.378)a |
| Obese | 1.322 (1.178–1.483)a | 1.342 (1.149–1.567)a |
| Cognitive Performance Score | ||
| Intact | Ref. | Ref. |
| Borderline intact/Mild Impairment | 1.006 (0.896–1.131) | 1.071 (0.916–1.252) |
| Moderate impairment | 0.997 (0.876–1.134) | 0.943 (0.792–1.123) |
| Moderate-severe/Severe/Very Severe impairment | 0.526 (0.440–0.628)a | 0.527 (0.406–0.683)a |
| CHESS | ||
| Score of 0 | Ref. | Ref. |
| Score of 1 or 2 | 0.928 (0.840–1.025) | 0.852 (0.746–0.974)a |
| Score of 3 | 0.729 (0.615–0.865)a | 0.820 (0.650–1.034) |
| Score of 4 or 5 | 0.650 (0.475–0.890)a | 0.811 (0.527–1.248 |
| Activities of Daily Living | 0.989 (0.980–0.997)a | 0.976 (0.965–0.987)a |
| Elixhauser/Other Comorbidities | ||
| Aphasia | 0.605 (0.457–0.801)a | 0.574 (0.373–0.882)a |
| Congestive Heart Failure | 0.839 (0.755–0.934)a | 0.865 (0.747–1.002) |
| Hypertension, Uncomplicated | 1.295 (1.184–1.416)a | 1.054 (0.933–1.191) |
| Weight Loss | 0.753 (0.635–0.893)a | 0.745 (0.580–0.958)a |
| Bladder Continence | ||
| Continent | Ref. | Ref. |
| Usually Continent | 1.244 (1.076–1.438)a | 1.099 (0.903–1.337) |
| Occasionally Incontinent | 1.586 (1.370–1.837)a | 1.494 (1.228–1.819)a |
| Frequently Incontinent | 1.538 (1.343–1.761)a | 1.517 (1.263–1.823)a |
| Incontinent | 1.083 (0.915–1.281) | 1.240 (0.973–1.582) |
| No Bladder Continence Appliance or Program | 1.214 (1.081–1.363)a | 0.997 (0.852–1.166) |
| Bowel Continence | ||
| Continent | Ref. | Ref. |
| Usually Continent | 0.729 (0.624–0.852)a | 0.943 (0.771–1.153) |
| Occasionally Incontinent | 0.901 (0.748–1.086) | 0.768 (0.593–0.994)a |
| Frequently Incontinent | 0.750 (0.636–0.885)a | 0.641 (0.508–0.809)a |
| Incontinent | 0.678 (0.568–0.808)a | 0.583 (0.451–0.753)a |
| Urinary Tract Infection in Last 30 Days | 1.104 (0.995–1.225) | 1.168 (1.015–1.344)a |
| Gait | ||
| Unsteady Gait | 1.019 (0.894–1.162) | 0.939 (0.784–1.124) |
| Fell in Past 30 days | 1.032 (0.904–1.177) | 0.890 (0.739–1.071) |
| Hip Fracture in Last 180 Days | 0.825 (0.705–0.966)a | 0.679 (0.538–0.857)a |
| Other Fracture in Last 180 Days | 1.131 (1.037–1.235)a | 1.025 (0.911–1.155) |
| Balance While Sitting | ||
| Maintained position as required in test | Ref. | Ref. |
| Unsteady, but able to rebalance self without physical support | 1.183 (1.076–1.300)a | 1.064 (0.935–1.210) |
| Partial physical support during test or stands but does not follow directions for test | 0.252 (1.049–1.494)a | 1.057 (0.818–1.365) |
| Not able to attempt test without physical help | 1.250 (1.065–1.467)a | 1.348 (1.090–1.668)a |
| Concomitant Medications | ||
| Calcium Channel Blockers | 1.029 (0.935–1.134) | 1.156 (1.016–1.315)a |
| Cognitive Enhancers | 1.049 (1.044–1.369)a | 1.196 (1.044–1.369)a |
| Antiparkinson | 0.902 (0.782–1.040) | 1.354 (1.129–1.625)a |
| Antipsychotics | 0.472 (0.423–0.526)a | 0.873 (0.753–1.012) |
| Antivertigo | 0.267 (0.235–0.303)a | 0.729 (0.612–0.867)a |
| Anxiolytic Sedative or Hypnotic Agent | 0.671 (0.592–0.760)a | 1.025 (0.865–1.214) |
| Antidepressant | 0.602 (0.549–0.660)a | 1.301 (1.148–1.474)a |
| ARB | 1.004 (0.874–1.152) | 1.305 (1.097–1.552)a |
| Alpha Blockers | 1.038 (0.909–1.186) | 1.327 (1.116–1.579)a |
| Anticonvulsant | 0.727 (0.656–0.806)a | 0.930 (0.810–1.067) |
| Vasodilators | 0.584 (0.515–0.662)a | 0.990 (0.836–1.172) |
| Benzodiazepines | 2.058 (1.251–3.387)a | 1.885 (0.993–3.578) |
| Anticholinergic Burden Score | 1.478 (1.445–1.511)a | 0.807 (0.780–0.835)a |
aIndicates statistical significance